Immunitas Therapeutics

Immunitas Therapeutics

MA - Waltham
Biotechnology
WebsiteLinkedInCareers Page

Focus: Single cell genomics-based drug discovery

Immunitas Therapeutics is a life sciences company focused on Single cell genomics-based drug discovery.

Oncology
Funding Stage
SERIES B
Open Jobs
0

Products & Portfolio (1)

ANKTIVA
nogapendekin alfa inbakicept-pmln
Growth
INTRAVESICAL · SOLUTION
inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4 and CD8 T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8 , and memory T cells without proliferation of immuno-suppressive Treg cells. In vivo, intravesicular nogapendekin alfa inbakicept-pmln alone or in combination with BCG showed anti-tumor activity when compared to BCG alone, in a carcinogen-induced model of bladder cancer in immunocompetent rats.
without papillary tumors
2024
30

Pipeline & Clinical Trials

Phase 1/2
Clinical Trials (1)
NCT05565417Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 1 approved product, 1 clinical trial
Top TAs: Oncology
Portfolio Health
Growth1 (100%)
1 total products
Therapeutic Area Focus
Oncology
1 marketed
Marketed
Pipeline